From the Editor

The Oncology Nursing Society (ONS) held its 38th Annual Congress in May while the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) took place this month. Read More ›

This month’s Fifth Annual Review issue of The Oncology Nurse-APN/PA® (TON) highlights some of the recent advances in anticancer care. Read More ›

This issue of The Oncology Nurse-APN/PA (TON) is packed with news about what is happening in the world of oncology research and brings you information that helps you in your day-to-day practice. We highlight news from the 2013 Genitourinary Cancers Symposium and the Hematology/Oncology Pharmacy Association (HOPA) 9th Annual Conference. Read More ›

With this issue of The Oncology Nurse-APN/PA (TON), we continue our coverage of the news from the 54th Annual Meeting of the American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS). Read More ›

Welcome to the first issue of The Oncology Nurse-APN/PA (TON) for 2013. We’ll be publishing 11 issues this year, keeping you up-to-date about what is happening in the world of oncology research and bringing you information that helps you in your day-to-day practice. Read More ›

This issue of The Oncology Nurse-APN/PA (TON) brings you highlights of the news from the 2012 American Society for Radiation Oncology (ASTRO) annual meeting. Part of our ASTRO coverage includes the results of a study that show that many patients with incurable lung cancer misunderstood the goals of palliative radiation therapy. Read More ›

October is National Breast Cancer Awareness Month. The October 1, 2012, presidential proclamation acknowledging this points out that “Breast cancer touches the lives of Americans from every background and in every community across our Nation.” Read More ›

In this month’s issue of The Oncology Nurse-APN/PA (TON), we bring you the news from the European Society for Medical Oncology 2012 Con­gress. Some of the most exciting news came from the update of the PROFILE 1007 trial, with results showing that crizotinib was more effective than standard chemo­therapy with pemetrexed or doce­taxel as a second-line treatment for non–small cell lung cancer. We also cover the latest treatment information about pancreatic neuroendocrine tumors, which, as one presenter noted, is “not a rare disease any longer.” Read More ›

Page 8 of 8


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: